Novo Nordisk filed a lawsuit against rival Eli Lilly, accusing the latter of false advertising regarding weight-loss medications. <\/p>\n
Novo Nordisk said Eli Lilly\u2019s claims that its medications work better than Novo\u2019s are not true, Reuters<\/a> reported. <\/p>\n The lawsuit was filed in district court in New Jersey, The Wall Street Journal<\/a> reported.<\/p>\n The lawsuit alleges that Lilly used high doses of its Zepbound to compare with lower doses of Wegovy and Ozempic while also using outdated trials. <\/p>\n \u201cThe ads are maliciously and deceptively false because \u200bLilly knowingly cites outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk\u2019s medicines,\u201d Novo Nordisk said in the suit. <\/p>\n Novo Nordisk sent Eli Lilly a cease-and-desist letter in April but said they did not receive a response, according to The Wall Street Journal<\/a>.<\/p>\n An Eli Lilly spokesperson responded, \u201cRather than compete on the merits of its products, Novo is asking a court to stop Lilly from communicating the \u200bresults of that trial. We will continue to focus on the science and defend against this lawsuit vigorously.\u201d<\/p>\n